Xyotax paclitaxel poliglumex: Suspended Phase III enrollment

CTIC suspended enrollment in the open-label Phase III PIONEER trial to look at differences in early cycle deaths observed between arms of the study.

Read the full 242 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE